[go: up one dir, main page]

HN2010002157A - Antagonistas de la trayectoria hedgehog de ftalazina disustituida - Google Patents

Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Info

Publication number
HN2010002157A
HN2010002157A HN2010002157A HN2010002157A HN2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A
Authority
HN
Honduras
Prior art keywords
hedgehog
antagonists
ftalazina
disttituted
history
Prior art date
Application number
HN2010002157A
Other languages
English (en)
Inventor
Philip Arthur Hipsikind
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2010002157A publication Critical patent/HN2010002157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANTAGONISTAS DE LA TRAYECTORIA HEDGEHOG Y, MAS ESPECIFICAMENTE, A NUEVAS FTALAZINAS 1,4- DISUSTITUIDAS Y USO TERAPEUTICO DE LAS MISMAS. LA TRAYECTORIA DE SEÑALIZACION HEDGEHOG (Hn) JUEGA UN PAPEL IMPORTANTE EN LA FORMACION DE PATRON EMBRIONICO Y MANTENIMIENTO DEL TEJIDO EN ADULTOS DIRIGIENDO LA DIFERENCIACION Y PROLIFERACION CELULAR.
HN2010002157A 2008-04-29 2010-10-21 Antagonistas de la trayectoria hedgehog de ftalazina disustituida HN2010002157A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29

Publications (1)

Publication Number Publication Date
HN2010002157A true HN2010002157A (es) 2014-09-08

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010002157A HN2010002157A (es) 2008-04-29 2010-10-21 Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Country Status (22)

Country Link
US (1) US7981892B2 (es)
EP (1) EP2294061A2 (es)
JP (1) JP5442717B2 (es)
KR (1) KR101260116B1 (es)
CN (1) CN102066353B (es)
AU (1) AU2009241561B2 (es)
BR (1) BRPI0911618A2 (es)
CA (1) CA2723042A1 (es)
CO (1) CO6300945A2 (es)
CR (1) CR11741A (es)
DO (1) DOP2010000302A (es)
EA (1) EA201071248A1 (es)
EC (1) ECSP10010577A (es)
HN (1) HN2010002157A (es)
IL (1) IL208211A0 (es)
MA (1) MA32349B1 (es)
MX (1) MX2010011948A (es)
MY (1) MY159491A (es)
NZ (1) NZ588001A (es)
UA (1) UA102250C2 (es)
WO (1) WO2009134574A2 (es)
ZA (1) ZA201006695B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011948A (es) 2008-04-29 2010-12-14 Lilly Co Eli Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
NZ591945A (en) 2008-11-03 2012-10-26 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
PT2358698E (pt) 2008-11-17 2012-10-24 Lilly Co Eli Antagonistas da via hedgehog de piridazina tetrasubstituída
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
PH12012500911A1 (en) * 2009-11-18 2012-11-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
WO2014043608A2 (en) * 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
PE20251293A1 (es) * 2022-09-23 2025-05-14 Merck Sharp And Dohme Llc Derivados de ftalazina utiles como inhibidores de la proteina receptora 3 similar a nod

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
IL124461A (en) * 1996-01-15 2000-07-26 Janssen Pharmaceutica Nv Angiogenesis inhibiting 3-(1,2,4-thiadiazol-5-yl)piperazine pyridazine derivatives their preparation and pharmaceutical compositions containing them
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
AU768130B2 (en) 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR101225018B1 (ko) * 2004-09-02 2013-01-23 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
MY156814A (en) * 2007-03-15 2016-03-31 Novartis Ag Organic compounds and their uses
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
CA2697682A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling
MX2010011948A (es) 2008-04-29 2010-12-14 Lilly Co Eli Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
NZ591945A (en) 2008-11-03 2012-10-26 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
PT2358698E (pt) 2008-11-17 2012-10-24 Lilly Co Eli Antagonistas da via hedgehog de piridazina tetrasubstituída
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
CR11741A (es) 2011-01-05
JP2011527666A (ja) 2011-11-04
JP5442717B2 (ja) 2014-03-12
DOP2010000302A (es) 2010-11-15
US7981892B2 (en) 2011-07-19
AU2009241561B2 (en) 2013-05-16
WO2009134574A2 (en) 2009-11-05
EP2294061A2 (en) 2011-03-16
US20110046143A1 (en) 2011-02-24
NZ588001A (en) 2012-06-29
BRPI0911618A2 (pt) 2019-09-24
CO6300945A2 (es) 2011-07-21
ECSP10010577A (es) 2010-11-30
CA2723042A1 (en) 2009-11-05
UA102250C2 (ru) 2013-06-25
MY159491A (en) 2017-01-13
ZA201006695B (en) 2012-09-26
IL208211A0 (en) 2010-12-30
CN102066353A (zh) 2011-05-18
MA32349B1 (fr) 2011-06-01
CN102066353B (zh) 2013-12-11
KR101260116B1 (ko) 2013-05-02
AU2009241561A1 (en) 2009-11-05
WO2009134574A3 (en) 2014-09-04
KR20100126580A (ko) 2010-12-01
MX2010011948A (es) 2010-12-14
EA201071248A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
HN2010002157A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CL2019002067A1 (es) Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050).
MX386187B (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
CY1120054T1 (el) Ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νευρολογικων και ψυχολογικων διαταραχων
CR20120051A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
BRPI0912542A2 (pt) derivados de ácido 3,5-diamino-cloro-pirazina-2-carboxílico e seu uso como bloqueadores do canal de sódio epitelial para o tratamento de vias aéreas.
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
MX372722B (es) Sulfonamidas de aza-aril 1h-pirazol-1-il benceno
MX375715B (es) Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos.
MX382599B (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina.
MX2012013945A (es) Nuevas formas de rifaximina y usos de las mismas.
LT3045474T (lt) Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
UY29186A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CU20110215A7 (es) Piperidinas sustituidas
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
ECSP067039A (es) Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5
UY34043A (es) Isoxazolinas como agentes terapéuticos
CL2009001158A1 (es) Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
CL2009000367A1 (es) Compuestos derivados de tiofen-amidas, inhibidores de los factores de la coagulacion xa y trombina; procedimiento de preparacion; composicion farmaceutica; y uso en trastornos cardiovasculares, enfermedades tromboembolicas o restenosis.
UY33153A (es) Formulación tópica oftálmica de péptidos